+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Global Genetic Testing Market by Product (Consumables & Equipment, Software & Services), Test Type (Carrier Testing, Diagnostic Testing, New Born Screening), Technology, Application, Distribution Channel, End-User - Forecast 2023-2030

  • PDF Icon

    Report

  • 186 Pages
  • March 2024
  • Region: Global
  • 360iResearch™
  • ID: 4904587
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Genetic Testing Market size was estimated at USD 10.45 billion in 2022, USD 11.89 billion in 2023, and is expected to grow at a CAGR of 13.99% to reach USD 29.79 billion by 2030.

Genetic testing comprises a diverse range of products and services to analyze an individual's DNA to identify specific genes, chromosomes, or proteins linked to inherited traits, disease predispositions, or therapeutic responses. Various sectors, including clinical diagnostics, pharmaceutical research and development, biotechnology innovation, forensics, nutrigenomics, and direct-to-consumer services, are important business sectors in this market. Several factors have contributed to the significant growth of the genetic testing market in recent years. These include advancements in DNA sequencing technologies such as next-generation sequencing (NGS), increased awareness about early diagnosis benefits through genetic testing, growing prevalence of genetic disorders, an aging population, rising demand for personalized medicine, expanding use of direct-to-consumer genetic testing services, and supportive government policies coupled with favorable reimbursement scenarios. Emerging opportunities within the genetic testing market involve integrating with other cutting-edge technologies such as artificial intelligence (AI), big data analytics, and telemedicine platforms; entering high-growth markets such as Asia-Pacific; fostering public-private partnerships to bolster genomic research initiatives; applying precision medicine programs tailored to individual genetic profiles; and using liquid biopsy technology for early cancer detection via circulating tumor DNA (ctDNA) in blood samples. Nevertheless, the growth potential is hampered by several limitations and challenges that include ethical concerns regarding privacy issues and misuse of genetic information; insufficient public awareness about genetic testing's significance; affordability constraints due to high costs of advanced tests for certain segments of the population; inconsistent guidelines and regulations across countries; concerns over false results leading to misinterpretation by healthcare professionals and patients alike; and workforce shortage in areas such as certified genetic counselors.

Innovation and research efforts in the genetic testing market should be geared towards developing novel gene-editing technologies such as CRISPR-Cas9 for precision editing capabilities, enhancing bioinformatics tools for better interpretation of vast genomic data generated by high-throughput sequencing platforms, exploring new applications in non-invasive prenatal testing (NIPT) using cell-free fetal DNA (cffDNA); discovering unique biomarkers for disease conditions that can be targeted through pharmacogenomics approaches; and expanding into fields such as environmental genomics to assess individual responses to various environmental factors.

Regional Insights

The advanced healthcare infrastructure and strong government support for research and development in the Americas have led to a thriving genetic testing market. However, regulatory challenges remain as manufacturers must adhere to strict guidelines set by agencies such as the Food Drug Administration (FDA). Europe presents a diverse landscape with varying regulations across its member countries. The UK's Brexit has caused uncertainty in its regulatory framework. Manufacturers or providers must tailor their strategies to each country's specific requirements. The Middle East & Africa have potential for genetic testing providers due to growing populations and the increasing prevalence of chronic diseases. However, limited healthcare infrastructure and a lack of awareness about genetic testing services create challenges for entry into these markets. The APAC region offers major growth opportunities within China, Japan, and India as their large patient populations require accurate diagnosis and proactive management of hereditary conditions. Despite regulatory hurdles similar to those in developed countries, there is room for innovation catering to local context needs. Genetic testing is becoming vital to personalized medicine and preventive healthcare in developed countries; however, navigating complex regulations is crucial. In emerging countries, where potential lies for market expansion investment in local partnerships, educational initiatives, and infrastructure development. Recent news highlights collaborations aimed at improving offerings within the genetic testing market. Global genetic testing offers numerous opportunities to stay informed about regional trends and adapt strategies accordingly, ultimately contributing meaningfully to public health outcomes worldwide.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Genetic Testing Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Genetic Testing Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Genetic Testing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agilent Technologies, Inc., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Blueprint Genetics Oy, Centogene N.V., Color Health, Inc., CooperSurgical Inc., Editas Medicine, Inc., ELITechGroup SAS, Eugene Labs Pty Ltd., Eurofins Scientific SE, F. Hoffmann-La Roche AG, Fulgent Genetics, Inc., Gene by Gene, Ltd., GeneDx, LLC, Illumina, Inc., Invitae Corporation, Laboratory Corporation of America Holdings, Living DNA Ltd., Macrogen, Inc., MyHeritage Ltd., Myriad Genetics, Inc., Natera, Inc., Newtopia Inc., PathogenDx Corporation, PerkinElmer Inc., Qiagen N.V., Sanofi S.A., and Thermo Fisher Scientific Inc.

Market Segmentation & Coverage

This research report categorizes the Genetic Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Product
    • Consumables & Equipment
    • Software & Services
  • Test Type
    • Carrier Testing
    • Diagnostic Testing
    • New Born Screening
    • Pharmacogenomics
    • Preimplantation Testing
    • Prenatal Testing
    • Presymptomatic & Predictive Testing
  • Technology
    • Cytogenetics
    • DNA Sequencing
    • Gene Expression Profiling
    • Microarrays
    • PCR
  • Application
    • Autoimmune Disorders
    • Cancer
    • Chronic Diseases
    • Genetic Disorders
    • Neurodegenerative Diseases
  • Distribution Channel
    • Offline
    • Online
  • End-User
    • Diagnostic Laboratories
    • Home Setting
    • Hospitals & Clinics
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as

  1. What is the market size and forecast of the Genetic Testing Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Genetic Testing Market?
  3. What are the technology trends and regulatory frameworks in the Genetic Testing Market?
  4. What is the market share of the leading vendors in the Genetic Testing Market?
  5. Which modes and strategic moves are suitable for entering the Genetic Testing Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Genetic Testing Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Prevalence of genetic and oncology disorders and need for precision medicine
5.1.1.2. Government initiatives for genetic testing and rise of self-test kits
5.1.2. Restraints
5.1.2.1. Concerns associated with false positives & negatives of genetic tests
5.1.3. Opportunities
5.1.3.1. Ongoing research and new developments in genetic testing technologies
5.1.3.2. Emergence of genetic testing with telehealth and digital health platforms
5.1.4. Challenges
5.1.4.1. Logistical barriers and privacy concerns to genetic testing
5.2. Market Segmentation Analysis
5.2.1. Product: Penetration of software and services for efficient data management and analysis
5.2.2. Test Type: Emphasis on diagnostic testing to perform particular disease dignosis
5.2.3. Technology: Increasing shift toward DNA sequencing for precise gene identification and disease diagnosis
5.2.4. Application: Rising adoption of genetic testing to detect early signs of cancer
5.2.5. Distribution Channel: Deployment of genetic testing products on online platforms
5.2.6. End-User: Extensive use of genetic testing solutions in hospitals & clinics for disease diagnosis and treatment planning
5.3. Market Trend Analysis
5.3.1. Technological advances and presence of established pharmaceutical companies enhance the genetic testing market growth in the Americas
5.3.2. Increasing chronic disorders and expanding healthcare infrastructure supports genetic testing in the APAC region.
5.3.3. Government initiatives and increasing demand for personalized medicine expand genetic testing market growth in the EMEA region.
5.4. Cumulative Impact of COVID-19
5.5. Cumulative Impact of Russia-Ukraine Conflict
5.6. Cumulative Impact of High Inflation
5.7. Porter’s Five Forces Analysis
5.7.1. Threat of New Entrants
5.7.2. Threat of Substitutes
5.7.3. Bargaining Power of Customers
5.7.4. Bargaining Power of Suppliers
5.7.5. Industry Rivalry
5.8. Value Chain & Critical Path Analysis
5.9. Regulatory Framework
6. Genetic Testing Market, by Product
6.1. Introduction
6.2. Consumables & Equipment
6.3. Software & Services
7. Genetic Testing Market, by Test Type
7.1. Introduction
7.2. Carrier Testing
7.3. Diagnostic Testing
7.4. New Born Screening
7.5. Pharmacogenomics
7.6. Preimplantation Testing
7.7. Prenatal Testing
7.8. Presymptomatic & Predictive Testing
8. Genetic Testing Market, by Technology
8.1. Introduction
8.2. Cytogenetics
8.3. DNA Sequencing
8.4. Gene Expression Profiling
8.5. Microarrays
8.6. PCR
9. Genetic Testing Market, by Application
9.1. Introduction
9.2. Autoimmune Disorders
9.3. Cancer
9.4. Chronic Diseases
9.5. Genetic Disorders
9.6. Neurodegenerative Diseases
10. Genetic Testing Market, by Distribution Channel
10.1. Introduction
10.2. Offline
10.3. Online
11. Genetic Testing Market, by End-User
11.1. Introduction
11.2. Diagnostic Laboratories
11.3. Home Setting
11.4. Hospitals & Clinics
12. Americas Genetic Testing Market
12.1. Introduction
12.2. Argentina
12.3. Brazil
12.4. Canada
12.5. Mexico
12.6. United States
13. Asia-Pacific Genetic Testing Market
13.1. Introduction
13.2. Australia
13.3. China
13.4. India
13.5. Indonesia
13.6. Japan
13.7. Malaysia
13.8. Philippines
13.9. Singapore
13.10. South Korea
13.11. Taiwan
13.12. Thailand
13.13. Vietnam
14. Europe, Middle East & Africa Genetic Testing Market
14.1. Introduction
14.2. Denmark
14.3. Egypt
14.4. Finland
14.5. France
14.6. Germany
14.7. Israel
14.8. Italy
14.9. Netherlands
14.10. Nigeria
14.11. Norway
14.12. Poland
14.13. Qatar
14.14. Russia
14.15. Saudi Arabia
14.16. South Africa
14.17. Spain
14.18. Sweden
14.19. Switzerland
14.20. Turkey
14.21. United Arab Emirates
14.22. United Kingdom
15. Competitive Landscape
15.1. FPNV Positioning Matrix
15.2. Market Share Analysis, By Key Player
15.3. Competitive Scenario Analysis, By Key Player
15.3.1. Merger & Acquisition
15.3.1.1. Sema4 to acquire genetic testing firm GeneDx for USD 623 Million
15.3.1.2. healthOme Acquires Kailos Genetics
15.3.1.3. Agilent Announces Acquisition of Avida Biomed, Developer of High-Performance NGS Target Enrichment Workflows for Cancer Research
15.3.2. Agreement, Collaboration, & Partnership
15.3.2.1. Scribe and Sanofi expand genetic therapy development deal
15.3.2.2. CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders
15.3.2.3. Invitae Announces Partnership with Epic to Streamline Genetic Testing
15.3.3. New Product Launch & Enhancement
15.3.3.1. Devyser launches two new genetic testing solutions for hereditary cancer
15.3.3.2. Blueprint Genetics introduces the new Screening Tests family; giving actionable insights for family planning, and future health
15.3.3.3. Kindbody Brings Genetic Testing In-House with the Launch of Kindlabs
15.3.3.4. PathogenDx Expands Reach of Its Patented Multiplexed Molecular Testing Technology, Bringing It to the Clinical, Food and Agriculture Sectors
15.3.4. Investment & Funding
15.3.4.1. DNA company Asa Ren raises USD 8M and more briefs
15.3.4.2. Genetic Testing Firm Delve Gets USD 35 Million in VC Funding
15.3.5. Award, Recognition, & Expansion
15.3.5.1. FBI approves QIAGEN’s NGS-based ForenSeq MainstAY workflow for the U.S. National DNA Index System (NDIS)
15.3.5.2. MapMyGenome launches India’s First DNA Test For Personalized Skin And Hair Care
15.3.5.3. Grand Launching Of DNATEST.ID, A Comprehensive Dna Test In Indonesia
15.3.5.4. MyHeritage Releases cM Explainer to Predict Familial Relationships Between DNA Matches with Greater Accuracy
16. Competitive Portfolio
16.1. Key Company Profiles
16.1.1. Abbott Laboratories
16.1.2. Agilent Technologies, Inc.
16.1.3. Becton, Dickinson and Company
16.1.4. Bio-Rad Laboratories, Inc.
16.1.5. Blueprint Genetics Oy
16.1.6. Centogene N.V.
16.1.7. Color Health, Inc.
16.1.8. CooperSurgical Inc.
16.1.9. Editas Medicine, Inc.
16.1.10. ELITechGroup SAS
16.1.11. Eugene Labs Pty Ltd.
16.1.12. Eurofins Scientific SE
16.1.13. F. Hoffmann-La Roche AG
16.1.14. Fulgent Genetics, Inc.
16.1.15. Gene by Gene, Ltd.
16.1.16. GeneDx, LLC
16.1.17. Illumina, Inc.
16.1.18. Invitae Corporation
16.1.19. Laboratory Corporation of America Holdings
16.1.20. Living DNA Ltd.
16.1.21. Macrogen, Inc.
16.1.22. MyHeritage Ltd.
16.1.23. Myriad Genetics, Inc.
16.1.24. Natera, Inc.
16.1.25. Newtopia Inc.
16.1.26. PathogenDx Corporation
16.1.27. PerkinElmer Inc.
16.1.28. Qiagen N.V.
16.1.29. Sanofi S.A.
16.1.30. Thermo Fisher Scientific Inc.
16.2. Key Product Portfolio
17. Appendix
17.1. Discussion Guide
17.2. License & Pricing
List of Figures
FIGURE 1. GENETIC TESTING MARKET RESEARCH PROCESS
FIGURE 2. GENETIC TESTING MARKET SIZE, 2022 VS 2030
FIGURE 3. GENETIC TESTING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GENETIC TESTING MARKET SIZE, BY REGION, 2022 VS 2030 (%)
FIGURE 5. GENETIC TESTING MARKET SIZE, BY REGION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 6. GENETIC TESTING MARKET DYNAMICS
FIGURE 7. GENETIC TESTING MARKET SIZE, BY PRODUCT, 2022 VS 2030 (%)
FIGURE 8. GENETIC TESTING MARKET SIZE, BY PRODUCT, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 9. GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2022 VS 2030 (%)
FIGURE 10. GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 11. GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2022 VS 2030 (%)
FIGURE 12. GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 13. GENETIC TESTING MARKET SIZE, BY APPLICATION, 2022 VS 2030 (%)
FIGURE 14. GENETIC TESTING MARKET SIZE, BY APPLICATION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 15. GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2022 VS 2030 (%)
FIGURE 16. GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 17. GENETIC TESTING MARKET SIZE, BY END-USER, 2022 VS 2030 (%)
FIGURE 18. GENETIC TESTING MARKET SIZE, BY END-USER, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS GENETIC TESTING MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 20. AMERICAS GENETIC TESTING MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES GENETIC TESTING MARKET SIZE, BY STATE, 2022 VS 2030 (%)
FIGURE 22. UNITED STATES GENETIC TESTING MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC GENETIC TESTING MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC GENETIC TESTING MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA GENETIC TESTING MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA GENETIC TESTING MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 27. GENETIC TESTING MARKET, FPNV POSITIONING MATRIX, 2022
FIGURE 28. GENETIC TESTING MARKET SHARE, BY KEY PLAYER, 2022

Companies Mentioned

  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Blueprint Genetics Oy
  • Centogene N.V.
  • Color Health, Inc.
  • CooperSurgical Inc.
  • Editas Medicine, Inc.
  • ELITechGroup SAS
  • Eugene Labs Pty Ltd.
  • Eurofins Scientific SE
  • F. Hoffmann-La Roche AG
  • Fulgent Genetics, Inc.
  • Gene by Gene, Ltd.
  • GeneDx, LLC
  • Illumina, Inc.
  • Invitae Corporation
  • Laboratory Corporation of America Holdings
  • Living DNA Ltd.
  • Macrogen, Inc.
  • MyHeritage Ltd.
  • Myriad Genetics, Inc.
  • Natera, Inc.
  • Newtopia Inc.
  • PathogenDx Corporation
  • PerkinElmer Inc.
  • Qiagen N.V.
  • Sanofi S.A.
  • Thermo Fisher Scientific Inc.

Methodology

Loading
LOADING...

Table Information